A Study of IBI363 in Subjects With Advanced Malignancies

NCT06468098 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

556

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: IBI363 + chemotherapy
DRUG: IBI363 + Investigator's Choice SOC

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.